Valid Evidence for Diagnosis and Treatment of Infections in the Intensive Care Unit: Beyond Randomized Control Trial Study Design (Trial Emulation and Machine Learning)
1. Infection in Critically Ill Patients and Randomized Control Trial
Beyond Randomized Control Trials
2. Conclusions
Funding
Conflicts of Interest
References
- Vincent, J.L.; Sakr, Y.; Singer, M.; Martin-Loeches, I.; MacHado, F.R.; Marshall, J.C.; Aditianingsih, D.; Finfer, S.; Pelosi, P.; Brazzi, L.; et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA 2020, 323, 1478–1487. [Google Scholar] [CrossRef] [PubMed]
- Vincent, J.L.; Bihari, D.J.; Suter, P.M.; Bruining, H.A.; White, J.; Nicolas Chanoin, M.H.; Wolff, M.; Spencer, R.C.; Hemmer, M. The Prevalence of Nosocomial Infection in Intensive Care Units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995, 274, 639–644. [Google Scholar] [CrossRef] [PubMed]
- Vincent, J.L.; Rello, J.; Marshall, J.; Silva, E.; Anzueto, A.; Martin, C.D.; Moreno, R.; Lipman, J.; Gomersall, C.; Sakr, Y.; et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA 2009, 302, 2323–2329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shields, R.K.; McCreary, E.K.; Marini, R.V.; Kline, E.G.; Jones, C.E.; Hao, B.; Chen, L.; Kreiswirth, B.N.; Doi, Y.; Clancy, C.J.; et al. Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections. Clin. Infect. Dis. 2020, 71, 667–671. [Google Scholar] [CrossRef] [PubMed]
- Levi, M.; Hovingh, G.K.; Cannegieter, S.C.; Vermeulen, M.; Büller, H.R. Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008, 111, 4471–4476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yusuf, E.; Bax, H.I.; Verkaik, N.J.; van Westreenen, M. An Update on Eight “New” Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. J. Clin. Med. 2021, 10, 1068. [Google Scholar] [CrossRef] [PubMed]
- U.S. Food and Drug Administration (FDA). Real-World Evidence. Available online: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence (accessed on 12 May 2022).
- Rosenbaum, P.R.; Rubin, D.B. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score. J. Am. Stat. Assoc. 1984, 79, 516. [Google Scholar] [CrossRef]
- Hernán, M.A.; Robins, J.M. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am. J. Epidemiol. 2016, 183, 758–764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Labrecque, J.A.; Swanson, S.A. Target trial emulation: Teaching epidemiology and beyond. Eur. J. Epidemiol. 2017, 326, 473–475. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peiffer-Smadja, N.; Rawson, T.M.; Ahmad, R.; Buchard, A.; Pantelis, G.; Lescure, F.X.; Birgand, G.; Holmes, A.H. Machine learning for clinical decision support in infectious diseases: A narrative review of current applications. Clin. Microbiol. Infect. 2020, 26, 584–595. [Google Scholar] [CrossRef] [PubMed]
- Dal-Ré, R.; Mentz, R.J.; Rosendaal, F.R. Thoughtful selection and use of scientific terms in clinical research: The case of ‘pragmatic’ trials. J. Investig. Med. 2021, 69, 1056–1058. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yusuf, E.; Rosendaal, F.R. Valid Evidence for Diagnosis and Treatment of Infections in the Intensive Care Unit: Beyond Randomized Control Trial Study Design (Trial Emulation and Machine Learning). J. Clin. Med. 2022, 11, 3600. https://doi.org/10.3390/jcm11133600
Yusuf E, Rosendaal FR. Valid Evidence for Diagnosis and Treatment of Infections in the Intensive Care Unit: Beyond Randomized Control Trial Study Design (Trial Emulation and Machine Learning). Journal of Clinical Medicine. 2022; 11(13):3600. https://doi.org/10.3390/jcm11133600
Chicago/Turabian StyleYusuf, Erlangga, and Frits R. Rosendaal. 2022. "Valid Evidence for Diagnosis and Treatment of Infections in the Intensive Care Unit: Beyond Randomized Control Trial Study Design (Trial Emulation and Machine Learning)" Journal of Clinical Medicine 11, no. 13: 3600. https://doi.org/10.3390/jcm11133600